Exploring the regulatory framework of psychedelics in the US & Europe.
Asian journal of psychiatry December 1, 2024 Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.
Psychedelic drug therapy shows promise for treating depression, PTSD, and anxiety, differing from conventional psychiatry in mechanism, legal status, and approach. This review covers the therapeutic potential, mechanisms, and regulatory approvals of psilocybin, MDMA, mescaline, ketamine, and LSD. It outlines legal aspects and regulations in the US and Europe, noting their Schedule I classification due to misuse potential. The FDA monitors psychedelics using expedited pathways and has issued guidance for clinical investigations. The EMA focuses on atypical psychedelics, addressing safety and efficacy challenges. Marketed products like Spravato nasal spray face limited distribution. Careful regulation and legislation are needed to harness therapeutic benefits.